New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review)

Xie,Qinfang; Sun,Mengjiao; Sun,Jing; Zheng,Ting; Wang,Manxia

doi:10.3892/etm.2020.9579

New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review)

Authors:
- Qinfang Xie
- Mengjiao Sun
- Jing Sun
- Ting Zheng
- Manxia Wang
View Affiliations

Affiliations: Department of Neurology, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China
Published online on: December 16, 2020 https://doi.org/10.3892/etm.2020.9579
Article Number: 148

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a group of immune‑mediated inflammatory demyelinating diseases mainly affecting the central nervous system. It is characterized by high risk of relapse and progression to disability. The frequent recurrences of neuromyelitis optica spectrum disorder often exacerbate the neurological dysfunction and severely affect the patient's quality of life. Conventional treatments for neuromyelitis optica spectrum disorder, including acute treatment and sequential therapy, aim to decrease the degree of disability and recurrences. In recent years, new monoclonal antibodies have yielded encouraging results. The present review discusses the research status and recent progress in the treatment of NMOSD with monoclonal antibodies.

View Figures

View References

1	Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, et al: International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 85:177–189. 2015.PubMed/NCBI View Article : Google Scholar
2	Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, et al: Multicentre comparison of a diagnostic assay: Aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry. 87:1005–1015. 2016.PubMed/NCBI View Article : Google Scholar
3	Forsthuber TG, Cimbora DM, Ratchford JN, Katz E and Stüve O: B cell-based therapies in CNS autoimmunity: Differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 11(1756286418761697)2018.PubMed/NCBI View Article : Google Scholar
4	Rastetter W, Molina A and White CA: Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 55:477–503. 2004.PubMed/NCBI View Article : Google Scholar
5	Iorio R, Damato V, Alboini PE and Evoli A: Efficacy and safety of rituximab for myasthenia gravis: A systematic review and meta-analysis. J Neurol. 262:1115–1119. 2015.PubMed/NCBI View Article : Google Scholar
6	Cree BA, Lamb S, Morgan K, Chen A, Waubant E and Genain C: An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 64:1270–1272. 2005.PubMed/NCBI View Article : Google Scholar
7	Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, et al: Treatment of neuromyelitis optica with rituximab: Retrospective analysis of 25 patients. Arch Neurol. 65:1443–1448. 2008.PubMed/NCBI View Article : Google Scholar
8	Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL and Sheremata WA: Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler. 17:1225–1230. 2011.PubMed/NCBI View Article : Google Scholar
9	Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, Bittner R, Canis M, Meinl E, Hohlfeld R and Kuempfel T: Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 76:1310–1315. 2011.PubMed/NCBI View Article : Google Scholar
10	Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS and Hemmer B: EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 17:1019–1032. 2010.PubMed/NCBI View Article : Google Scholar
11	Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O and Kümpfel T: Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 261:1–16. 2014.PubMed/NCBI View Article : Google Scholar
12	Damato V, Evoli A and Iorio R: Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. JAMA Neurol. 73:1342–1348. 2016.PubMed/NCBI View Article : Google Scholar
13	Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, Papeix C, Collongues N, Bourre B, Cohen M, et al: Evaluation of efficacy and tolerability of first-line therapies in NMOSD. Neurology. 94:e1645–e1656. 2020.PubMed/NCBI View Article : Google Scholar
14	Nikoo Z, Badihian S, Shaygannejad V, Asgari N and Ashtari F: Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: A randomized clinical trial. J Neurol. 264:2003–2009. 2017.PubMed/NCBI View Article : Google Scholar
15	Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, et al: Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 19:298–306. 2020.PubMed/NCBI View Article : Google Scholar
16	Kim SH, Huh SY, Jang H, Park NY, Kim Y, Jung JY, Lee MY, Hyun JW and Kim HJ: Outcome of pregnancies after onset of the neuromyelitis optica spectrum disorder. Eur J Neurol. 27:1546–1555. 2020.PubMed/NCBI View Article : Google Scholar
17	Kim SH, Huh SY, Lee SJ, Joung A and Kim HJ: A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 70:1110–1117. 2013.PubMed/NCBI View Article : Google Scholar
18	Marcinnò A, Marnetto F, Valentino P, Martire S, Balbo A, Drago A, Leto M, Capobianco M, Panzica G and Bertolotto A: Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 5(e498)2018.PubMed/NCBI View Article : Google Scholar
19	Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M, Hillert J, Langer-Gould A, Lycke J, Nilsson P, et al: Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 77:84–191. 2020.PubMed/NCBI View Article : Google Scholar
20	Holmøy T, Høglund RA, Illes Z, Myhr KM and Torkildsen Ø: Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol: Oct 3, 2020 (Online ahead of print).
21	Chen D, Gallagher S, Monson NL, Herbst R and Wang Y: Inebilizumab, a B cell-depleting anti-CD19 antibody for the treatment of autoimmune neurological diseases: Insights from preclinical studies. J Clin Med. 5(107)2016.PubMed/NCBI View Article : Google Scholar
22	Otero DC, Anzelon AN and Rickert RC: CD19 function in early and late B cell development: I. Maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol. 170:73–83. 2003.PubMed/NCBI View Article : Google Scholar
23	Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, et al: Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: A phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther. 18(131)2016.PubMed/NCBI View Article : Google Scholar
24	Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, Wesley J, Madani S, Barron G, Katz E and Flor A: Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler. 25:235–245. 2019.PubMed/NCBI View Article : Google Scholar
25	Paul F, Murphy O, Pardo S and Levy M: Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs. 27:265–271. 2018.PubMed/NCBI View Article : Google Scholar
26	Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, et al: Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 394:1352–1363. 2019.PubMed/NCBI View Article : Google Scholar
27	Frampton JE: Inebilizumab: First approval. Drugs. 80:1259–1264. 2020.PubMed/NCBI View Article : Google Scholar
28	Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, Taniguchi J and Kuwabara S: Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6. Mult Scler. 16:1443–1452. 2010.PubMed/NCBI View Article : Google Scholar
29	Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T and Yamamura T: Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA. 108:3701–3706. 2011.PubMed/NCBI View Article : Google Scholar
30	Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T and Yamamura T: Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 7(e841)2020.PubMed/NCBI View Article : Google Scholar
31	Bradl M, Kanamori Y, Nakashima I, Misu T, Fujihara K, Lassmann H and Sandkühler J: Pain in neuromyelitis optica - prevalence, pathogenesis and therapy. Nat Rev Neurol. 10:529–536. 2014.PubMed/NCBI View Article : Google Scholar
32	Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T and Yamamura T: Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study. Neurology. 82:1302–1306. 2014.PubMed/NCBI View Article : Google Scholar
33	Kang S, Tanaka T, Narazaki M and Kishimoto T: Targeting interleukin-6 signaling in clinic. Immunity. 50:1007–1023. 2019.PubMed/NCBI View Article : Google Scholar
34	Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S and Yamamura T: Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol. 23:827–831. 2013.PubMed/NCBI View Article : Google Scholar
35	Ayzenberg I, Kleiter I, Schröder A, Hellwig K, Chan A, Yamamura T and Gold R: Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol. 70:394–397. 2013.PubMed/NCBI View Article : Google Scholar
36	Ringelstein M, Ayzenberg I, Harmel J, Lauenstein AS, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, et al: Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol. 72:756–763. 2015.PubMed/NCBI View Article : Google Scholar
37	Lotan I, Charlson RW, Ryerson LZ, Levy M and Kister I: Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 39(101920)2019.PubMed/NCBI View Article : Google Scholar
38	Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, et al: Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): An open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 19:391–401. 2020.PubMed/NCBI View Article : Google Scholar
39	Araki M: Blockade of IL-6 signaling in neuromyelitis optica. Neurochem Int. 130(104315)2019.PubMed/NCBI View Article : Google Scholar
40	Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, et al: Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 381:2114–2124. 2019.PubMed/NCBI View Article : Google Scholar
41	Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, et al: Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 19:402–412. 2020.PubMed/NCBI View Article : Google Scholar
42	Lotan I, McGowan R and Levy M: Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: A systematic review of safety and efficacy. Curr Neuropharmacol: Apr 28, 2020 (Epub ahead of print). doi: 10.2174/1570159X18666200429010825.
43	Rosso M, Saxena S and Chitnis T: Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: A review of emerging treatment options. Expert Rev Neurother. 20:509–516. 2020.PubMed/NCBI View Article : Google Scholar
44	Heo YA: Satralizumab: First approval. Drugs. 80:1477–1482. 2020.PubMed/NCBI View Article : Google Scholar
45	Carpanini SM, Torvell M and Morgan BP: Therapeutic inhibition of the complement system in diseases of the central nervous system. Front Immunol. 10(362)2019.PubMed/NCBI View Article : Google Scholar
46	Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O and Wingerchuk DM: Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol. 12:554–562. 2013.PubMed/NCBI View Article : Google Scholar
47	Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, et al: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 381:614–625. 2019.PubMed/NCBI View Article : Google Scholar
48	Frampton JE: Eculizumab: A review in neuromyelitis optica spectrum disorder. Drugs. 80:719–727. 2020.PubMed/NCBI View Article : Google Scholar
49	Verkman AS, Smith AJ, Phuan PW, Tradtrantip L and Anderson MO: The aquaporin-4 water channel as a potential drug target in neurological disorders. Expert Opin Ther Targets. 21:1161–1170. 2017.PubMed/NCBI View Article : Google Scholar
50	Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, Bennett JL and Verkman AS: Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 71:314–322. 2012.PubMed/NCBI View Article : Google Scholar
51	Duan T, Tradtrantip L, Phuan PW, Bennett JL and Verkman AS: Affinity-matured ‘aquaporumab’ anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 162(107827)2020.PubMed/NCBI View Article : Google Scholar
52	Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M and Kanda T: Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry. 83:288–297. 2012.PubMed/NCBI View Article : Google Scholar
53	Mealy MA, Shin K, John G and Levy M: Bevacizumab is safe in acute relapses of neuromyelitis optica. Clin Exp Neuroimmunol. 6:413–418. 2015.PubMed/NCBI View Article : Google Scholar
54	Keating GM: Bevacizumab: A review of its use in advanced cancer. Drugs. 74:1891–1925. 2014.PubMed/NCBI View Article : Google Scholar
55	Mealy MA and Levy M: A pilot safety study of ublituximab, a monoclonal antibody against CD20, in acute relapses of neuromyelitis optica spectrum disorder. Medicine (Baltimore). 98(e15944)2019.PubMed/NCBI View Article : Google Scholar